A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.

Lilly

Status and phase: Completed; Phase 2

Conditions: Colorectal Cancer

Treatments: Drug: Oxaliplatin; Drug: ALIMTA

Study type: Interventional

Funder types: Industry

Identifiers

NCT00034619

H3E-MC-JMEP

5142

Details and patient eligibility

About

The purpose of this study is to assess the antitumor activity of ALIMTA plus Oxaliplatin combination therapy in patients with previously untreated advanced colorectal cancer

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of primary cancer of the colon or rectum
• Must have measurable disease
• Must be able to comply with study procedure

Exclusion criteria

• Prior chemotherapy for advanced disease
• Pregnancy or lactation
• Candidates for surgical resection of one or more metastatic foci
• Second primary cancer
• Inability to take folic acid or vitamin B12